An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility.

Low aqueous solubility is a common challenge in drug discovery and development and can lead to inconclusive biological assay results. Attaching small, polar groups that do not interfere with the bioactivity of the pharmacophore often improves solubility, but there is a dearth of viable neutral moieties available for this purpose. We have modified several poorly soluble drugs or drug candidates with the oxetanyl sulfoxide moiety of the DMSO analog MMS-350 and noted in most cases a moderate to large improvement of aqueous solubility. Furthermore, the membrane permeability of a test sample was enhanced compared to the parent compound.

[1]  G. Lajoie,et al.  Preparation of 1-[N-benzyloxycarbonyl-(1S)-1-amino-2-oxoethyl]-4-methyl-2,6,7-trioxabicyclo[2.2.2] octane: [Carbamic acid, [1-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)-2-oxoethyl]-, phenylmethyl ester, (S)-] , 2002 .

[2]  Peter Wipf,et al.  Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D. , 2011, ACS medicinal chemistry letters.

[3]  B. Lucht,et al.  ETHEREAL SOLVATION OF LITHIUM HEXAMETHYLDISILAZIDE : UNEXPECTED RELATIONSHIPS OF SOLVATION NUMBER, SOLVATION ENERGY, AND AGGREGATION STATE , 1995 .

[4]  Minoru Ishikawa,et al.  Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.

[5]  R B Greenwald,et al.  PEG drugs: an overview. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Gregory W. Kauffman,et al.  Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis. , 2013, Journal of medicinal chemistry.

[7]  E. Carreira,et al.  Oxetanes as versatile elements in drug discovery and synthesis. , 2010, Angewandte Chemie.

[8]  B. Hudson,et al.  Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. , 2012, Journal of medicinal chemistry.

[9]  G. Amidon,et al.  Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. , 2004, Molecular pharmaceutics.

[10]  A. Parekh,et al.  Receptors involved in mechanical responses to catecholamines in the circular muscle of guinea‐pig stomach treated with meclofenamate , 1990, British journal of pharmacology.

[11]  Matthew S. Johnson,et al.  Large-scale asymmetric synthesis of the bioprotective agent JP4-039 and analogs. , 2011, Organic letters.

[12]  P. Wipf,et al.  Design, Synthesis, and Biological Evaluation of PKD Inhibitors , 2011, Pharmaceutics.

[13]  Hong Wang,et al.  The mitochondria-targeted nitroxide JP4-039 augments potentially lethal irradiation damage repair. , 2009, In vivo.

[14]  Melissa M. Sprachman,et al.  A bifunctional dimethylsulfoxide substitute enhances the aqueous solubility of small organic molecules. , 2012, Assay and drug development technologies.

[15]  D. Small,et al.  Solubility of Bile Salts , 1969, Nature.

[16]  E. Carreira,et al.  Synthesis and stability of oxetane analogs of thalidomide and lenalidomide. , 2013, Organic letters.

[17]  Li Di,et al.  Bridging solubility between drug discovery and development. , 2012, Drug discovery today.

[18]  G L Amidon,et al.  Dissolution of acidic and basic compounds from the rotating disk: influence of convective diffusion and reaction. , 1986, Journal of pharmaceutical sciences.

[19]  P. Wipf,et al.  Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system. , 2005, Organic & biomolecular chemistry.

[20]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[21]  Nicolas Foloppe,et al.  Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds , 2004, J. Chem. Inf. Model..

[22]  P. Wipf,et al.  Synthesis of analogs of the radiation mitigator JP4-039 and visualization of BODIPY derivatives in mitochondria. , 2013, Organic & biomolecular chemistry.

[23]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[24]  Franz Schuler,et al.  Oxetanes in drug discovery: structural and synthetic insights. , 2010, Journal of medicinal chemistry.

[25]  C. Wermuth.  Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties , 2008 .

[26]  G. Lajoie,et al.  Preparation of 1‐[N‐Benzyloxycarbonyl‐(1S)‐1‐Amino‐2‐Oxoethyl]‐4‐Methyl‐2,6,7‐Trioxabicyclo[2.2.2]Octane , 2003 .

[27]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[28]  L. Pustilnik,et al.  Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors. , 2011, Journal of medicinal chemistry.

[29]  W. Fischer,et al.  Über Steroide. (33. Mitteilung). Über Glucoside des Desoxycorticosterons , 1942 .

[30]  M. Kansy,et al.  Solubility-Excipient Classification Gradient Maps , 2007, Pharmaceutical Research.

[31]  K. J. Mysels,et al.  Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. , 1992, Journal of lipid research.